On February 5, 2019, the Massachusetts judge presiding over the Zofran (ondansetron) birth defect multi-district ligation rejected GlaxoSmithKline’s (GSK) motion for summary judgment based on preemption. U.S. District Judge F. Dennis Saylor IV said that questions remain about whether GSK fully disclosed key data to the FDA about the anti-nausea drug, and if this data …. Read More
Did You Take Zofran During Your First Trimester?
Was Your Baby Born With Cleft Palate
or a Congenital Heart Defect?
Families involved in the Zofran (ondansetron) multidistrict litigation (“MDL”) alleged a 2016 label update for Zofran acknowledged for the first time that studies have shown an increased link between exposure to Zofran (ondansetron) and cardiovascular and cleft palate birth defects in babies born to women who took the drug while pregnant. However, the families contend …. Read More
Alabama mother Marquita Smiley began taking the generic form of anti-nausea drug Zofran (ondansetron) regularly during her first trimester to treat debilitating morning sickness—but when her son Zaidan was born with a critically underdeveloped heart, necessitating open heart surgery at just 3 days old, Marquita started to wonder whether the drug she took might have been …. Read More
At the April 2016 Mass Torts Made Perfect conference in Las Vegas later this month, Grant & Eisenhofer Director Elizabeth Graham, co-lead on the Plaintiffs’ Executive Committee of the Zofran (ondansetron) multi-district litigation, will speak to the latest developments in the litigation. Ms. Graham will cover the status of the over 230 cases centralized before …. Read More
In March 2016, with more than 200 lawsuits pending in the Zofran (ondansetron) federal multi-district litigation (“MDL”) in the District of Massachusetts, plaintiffs submitted their proposal on the sequence and effect of “Master Pleadings.” In a sequence of master pleadings, usually created for administrative reasons, master complaints collate claims brought in each case into a single …. Read More